Best Dermatology Companies in California, United States
The 132 best Dermatology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Alumis.
Ranked: Best Dermatology companies in California
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Alumis Developer of therapeutics for the treatment of auto-immune disease | $529M | 23 mo ago | 16 | 2003 | Martin Babler CEO | 88 patents TYK2 kinase inhibitor compounds and formulations for inflammatory disease treatment. | — |
| 2 | Evommune Developer of therapeutic options for chronic inflammatory disorders 60Growth top 16%Funding top 18%News top 25%Tech top 47% All 10 signals ▾Growthtop 16% Fundingtop 18% Newstop 25% Techtop 47% Fin. healthtop 47% Moattop 47% Patentsbottom 47% Marketbottom 46% Innovationbottom 42% Globalbottom 39% Growth: Revenue +86% YoY · Fresh capital in last 24 mo Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $268M | 4 mo ago | 33 | 2020 | — | 3 patents Small-molecule PKCθ inhibitors for immune‑modulating therapeutics | 2 launchs · 1 partnership |
| 3 | Rani Therapeutics Developer of technology for the oral delivery of large drug molecules 72Growth top 22%Funding top 23%Patents top 24%Talent top 27% All 11 signals ▾Growthtop 22% Fundingtop 23% Patentstop 24% Talenttop 27% Innovationtop 28% Newstop 30% Moattop 35% Techtop 45% Marketbottom 49% Fin. healthbottom 44% Globalbottom 42% Growth: Revenue +59% YoY · Fresh capital in last 24 mo Funding: Raised $234M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $234M | 7 mo ago | 163 | 2012 | Mir Imran Founder | 456 patents Oral ingestible devices for delivering biologic therapeutics to the gastrointestinal tract | 1 launch |
| 4 | Cutera Developer of energy-based medical aesthetic devices for the treatment of multiple diseases | $225M | 42 mo ago | 540 540 → 542 (+0%) | 1998 | David Mowry Founder & CEO | 99 patents Advanced laser dermatology devices for precise skin lesion and tissue treatment | 1 launch |
| 5 | DICE Developer of small molecule therapeutics for multiple disorders | $192M | 58 mo ago | 90 | 2013 | — | 36 patents Video surveillance analytics and network communication protocol technologies | — |
| 6 | Dermiria Topical products to treat psoriasis, hyperhidrosis, and acne. | $162M | 89 mo ago | 4 | 2011 | Thomas Wiggans CEO | — | — |
| 7 | Suneva Medical Developer of products for the regenerative aesthetic markets | $155M | 50 mo ago | 94 | 2009 | Pat Altavilla President and Chief Executive Officer | — | — |
| 8 | Revance Therapeutics Developer of neurotoxin aesthetic and therapeutic products for skin treatments | $155M | 151 mo ago | 597 | 2002 | Mark Foley Chief Executive Officer | 585 patents Patents concentrated in health & consumer products | — |
| 9 | Sienna Biopharmaceuticals Developer of silver plasmonic therapy for acne and permanent hair removal | $133M | 109 mo ago | 39 | 2016 | — | 71 patents Nanoparticle-based drug delivery and antimicrobial silver nanoplates for targeted therapeutic exposure | — |
| 10 | Kythera Biopharmaceuticals Pharmaceutical company specializing in aesthetics and therapeutic products | $107M | 177 mo ago | 113 | 2005 | — | 273 patents Bile‑acid injectable formulations and gene‑vector senolytic therapies targeting p16‑positive cells | — |
| 11 | Solta Range of aesthetic products | $105M | 151 mo ago | 6,355 | 1995 | — | — | 1 award |
| 12 | Arcutis Developer of immunotherapeutics solutions for dermatology | $94M | 80 mo ago | 296 296 → 451 (+52%) | 2016 | Bhaskar Chaudhuri Co-Founder | 48 patents Formulation technologies for roflumilast PDE4 inhibitor: crystal growth inhibition and skin delivery. | 1 launch |
| 13 | SkinMedica Science-backed skincare delivering transformative results through cleansers, moisturizers, sunscreens, and… | $94M | 204 mo ago | 132 | 1999 | Mitchel Goldman Co-Founder | 34 patents Topical dermatology formulations for exfoliation, melanin modulation, and conditioned cell‑culture media. | — |
| 14 | Lineage Cell Therapeutics Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders | $94M | 25 mo ago | 75 | 1990 | Brian Culley CEO | — | — |
| 15 | Miramar Labs Microwave therapy for Axillary Hyperhydrosis | $94M | 119 mo ago | 34 | 2006 | — | 113 patents Patents concentrated in health & consumer products | — |
| 16 | Forte Biosciences Developer of therapeutic solutions for treating inflammatory skin diseases | $82M | 19 mo ago | 9 | 2017 | Paul A. Wagner Founder & CEO | — | — |
| 17 | Thesan Pharmaceuticals Developer of therapeutics for disorders of the skin | $65M | 147 mo ago | 5 | 2011 | — | — | — |
| 18 | Recludix Pharma Provider of the online platform for drug discovery and development | $60M | 55 mo ago | 33 33 → 54 (+64%) | 2020 | Brian Hodous Co-Founder | — | — |
| 19 | Tioga Pharmaceuticals Developer of therapeutic solutiobs for the treatment of pruritus | $57M | 170 mo ago | 1 | 2005 | Stuart Collinson Founder & CEO | — | — |
| 20 | Menlo Therapeutics Developer of serlopitant drugs for the treatment of severe, chronic pruritus | $51M | 106 mo ago | 40 | 2011 | David Domzalski CEO & President | — | — |
| 21 | Creabilis Develops drugs for dermatology | $51M | 157 mo ago | 9 | 2003 | — | — | — |
| 22 | Adavium Medical Medical equipment and diagnostics manufacturing company | $47M | 122 mo ago | 1 | 2011 | — | — | — |
| 23 | AiVita Biomedical Developer of dendritic cell immunotherapy for cancer and markets stem cells based facial serum for skin care | $46M | 65 mo ago | 20 20 → 21 (+5%) | 2016 | — | 65 patents Cell membrane-bound signaling factor therapeutics for cancer immunotherapy | — |
| 24 | Histogen Developer of small molecule caspase inhibitors to restore immune function against infectious and inflammatory… | $45M | 47 mo ago | 22 | 2007 | Gail Naughton Founder & CEO | 97 patents Regenerative cell therapies and anti‑inflammatory biologics using caspase inhibitors and conditioned media | — |
| 25 | Candesant Provider of non-invasive energy device for treating hyperhidrosis | $44M | 36 mo ago | 3 | 2016 | Niquette Hunt Founder & CEO | — | — |
| 26 | Siolta Therapeutics Provider of microbiome therapeutics for treating multiple diseases | $42M | 27 mo ago | 14 | 2016 | Nikole Kimes Founder & CEO | — | — |
| 27 | Reviva Pharmaceuticals Develops therapeutic drugs for treatment of central nervous system | $41M | 108 mo ago | 4 | 2006 | Laxminarayan Bhat President and CEO | 161 patents Liposomal drug delivery of Brilaroxazine for psoriasis and arylpiperazine therapies for pulmonary fibrosis | — |
| 28 | Coapt Systems Bio-absorbable implants for use in cosmetic surgery | $39M | 197 mo ago | 50 | 2000 | Daniel Jacobs Founder & CEO | — | — |
| 29 | Reliant Technologies Online adult video platform offering diverse content and streaming services | $37M | 230 mo ago | 30 | 2001 | Maynard Howe Founder | 200 patents Fractional laser dermatology devices and advanced optical pattern generation for skin treatments | — |
| 30 | Neosil US-based dermatology-focused specialty pharma, acquired by Peplin | $32M | 229 mo ago | — | 2003 | Gene Bauer CEO | 4 patents Polycationic antimicrobial agents for medical and hygiene applications | — |
| 31 | Peplin Topical gel for the treatment of actinic (solar) keratosis. | $31M | 214 mo ago | — | 1999 | Tom Wiggans CEO | — | — |
| 32 | Pelage Pharmaceuticals Developer of therapeutics for hair loss treatment in men and women | $31M | 9 mo ago | — | 2018 | William Lowry Co-Founder & President | — | — |
| 33 | R2 Technologies Developer of device for skin care | $30M | 64 mo ago | 61 61 → 38 (-38%) | 2014 | — | — | 1 launch |
| 34 | Indomo Developer of device-enabled therapeutics intended to expand access to quality healthcare | $25M | 7 mo ago | — | 2021 | Rick Bente Co-Founder & CEO | — | — |
| 35 | Aneira Pharma Developer of a drug for alopecia treatment | $25M | 62 mo ago | 5 | 2019 | — | — | — |
| 36 | Lipidio Pharma Developer of therapeutics for dermatological disorders | $25M | 43 mo ago | 3 | 2019 | Gordon Foulkes CEO | — | — |
| 37 | DermTech Provider of adhesive patch biopsy for skin cancer diagnostics | $24M | 75 mo ago | 259 | 1996 | — | 97 patents Non‑invasive skin sampling and molecular diagnostics for skin cancer and disease detection | 2 launchs |
| 38 | RA Medical systems Developer of xenon chloride excimer lasers for treatment of skin and vascular diseases | $24M | 38 mo ago | 14 | 2002 | — | 3,753 patents Medical devices for patient monitoring, vascular occlusion, and cardiac pacing support. | — |
| 39 | Stemson Therapeutics Developer of stem cell based therapy for hair growth | $22M | 59 mo ago | 31 | 2019 | Geoff Hamilton Co-Founder & Chief Executive Officer | — | — |
| 40 | One Skin Technologies Developer of a skin therapy product to treat skin aging | $20M | 12 mo ago | 17 | 2016 | Mariana Boroni Co-Founder | — | — |
| 41 | CAGE Bio Developer of novel products based on ionic liquid platform for dermatology, inflammation, and immunology | $18M | 55 mo ago | 4 | 2016 | Samir Mitragotri Co-Founder | — | — |
| 42 | SelectION Provider of screening and development platform for drugs 11Funding top 36%Talent bottom 49%Global bottom 37%Market bottom 17% All 4 signals ▾Fundingtop 36% Talentbottom 49% Globalbottom 37% Marketbottom 17% Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $16M | 9 mo ago | 2 | 2017 | Andreas Klostermann Founder & CSO | — | — |
| 43 | Dermata Therapeutics Developer of therapeutics to treat a variety of dermatologic and ophthalmologic diseases | $16M | 5 mo ago | 8 | 2014 | Gerry Proehl President & CEO | — | — |
| 44 | miraDry Device for treating sweat and odor glands | $12M | 112 mo ago | 82 | 2010 | — | 25 patents Non‑invasive microwave energy for treating skin/tissue conditions like hyperhidrosis. | 1 partnership |
| 45 | Amplifica Developer of therapeutics for the treatment of androgenic alopecia | $12M | 43 mo ago | 10 | 2008 | Wajdie Ahmad Co-Founder | 38 patents Topical pharmaceutical formulations for stimulating hair growth and treating androgenetic alopecia. | — |
| 46 | Dermala Developer of therapeutics to treat and prevent diseases associated with the skin microbiome dysbiosis | $8M | 68 mo ago | 6 | 2014 | Lada Rasochova Founder & CEO | 36 patents Topical dermatology formulations for acne, eczema, and skin aging treatments | — |
| 47 | areygrey Provider of science-focused brand addressing the aging process of hair with a holistic approach | $4M | 43 mo ago | 100 | 2020 | — | — | — |
| 48 | Topaz Biosciences Developer of enzyme ingredients for skin microbiome rebalancing | $3M | 10 mo ago | — | 2022 | Teresa Shock Co-Founder | — | — |
| 49 | CellSound Provider of non-invasive aesthetic treatments using ultrasound technology. | $2M | 42 mo ago | — | 2022 | Mordechai Oderberg CEO | — | — |
| 50 | ResVita Bio Developer of therapies to treat skin diseases through engineered skin probiotics | $2M | 14 mo ago | 4 | 2021 | Jay Keasling Co-Founder | — | — |
Top 12 Dermatology companies in California
#1
Public · Sacramento, California · founded 2020 · 33 employees$268Mraised▾
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
- Feb 2026Post IPO$125M
- Oct 2024Series C$115M
- Jun 2023Series B$7.5M
- Mar 2023Series B$57.5M
#2
Public · San Jose, California · founded 2012 · 163 employees$234.1Mraised▾
Developer of technology for the oral delivery of large drug molecules. The company has a proprietary platform is capable of delivering a wide range of biologics for the treatment of various chronic diseases. The company develops RaniPill capsule has broad applications for the treatment of acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohn’s disease, hemophilia, diabetes, among other diseases.
- Oct 2025Post IPO$60.3M
- Dec 2020Series E$69M
- Nov 2020Series E$50M
- Feb 2018Series E$53M
#3
Public · San Diego, California · founded 2014 · 8 employees$15.7Mraised▾
Developer of therapeutics to treat a variety of dermatologic and ophthalmologic diseases. It offer XYNGARI a topical treatment derived from freshwater sponge extract targeting moderate‑to‑severe acne, with potential in psoriasis and rosacea and DMT410 a topical intradermal delivery system allowing botulinum toxin to penetrate via microchannels for aesthetic and medical skin treatments.
- Dec 2025Post IPO$4.1M
- Jan 2025Post IPO$2.5M
- Sep 2024Post IPO$3.5M
- May 2023Post IPO—
#4
Series B · Los Angeles, California · founded 2018$30.8Mraised▾
Developer of therapeutics for hair loss treatment in men and women. It provides a topical, non-invasive small molecule pharmacological platform that can be used to activate hair follicle stem cells and promote thick hair growth.
- Sep 2025Series B$120M
- Aug 2024Series A$14M
- Feb 2024Series A$16.8M
#5
Series B · San Francisco, California · founded 2021$25Mraised▾
Developer of device-enabled therapeutics intended to expand access to quality healthcare. The company focuses on creating fast-acting, at-home solutions for inflammatory skin conditions. It combines drug candidates with novel intradermal self-injection devices. The goal is to empower patients to perform treatments safely at home.
- Oct 2025Series B$25M
#6
Public · San Francisco, California · founded 2003 · 16 employees$529Mraised▾
Developer of therapeutics for the treatment of auto-immune disease. The lead candidate SK-001 is a potentially best-in-class TYK2 inhibitor for psoriasis treatment. The TYK2 is a gene that encodes a member of the tyrosine kinase which is a key mediator of inflammation and autoimmune diseases.
- Jul 2024Post IPO$40M
- Mar 2024Series C$259M
- 2023Series B—
- Jan 2022Series B$200M
#7
Series A · San Diego, California · founded 2017 · 2 employees$15.9Mraised▾
selectION provides screening and development platform for drugs. The company provides ion channel blockers by targeting additional potassium, sodium, calcium, and chloride channels, which will lead to other clinical applications in pain management and oncology. The company uses peptide structures derived from evolutionary tuned toxins from venomous animals like scorpions or cone snails as blueprints for its screening platform.
- Sep 2025Series A$20M
- Jun 2023Series A$11.8M
- May 2019Series A$4.1M
#8
Series A · San Francisco, California · founded 2016 · 17 employees$19.7Mraised▾
Developer of a skin therapy product to treat skin aging. The product developed a proprietary peptide OS-1 to address skin aging by preventing the accumulation of senescent cells in human skin. The products decrease cell senescence to improve skin health.
- May 2025Series A$20.4M
- Sep 2024Series A$7M
- Oct 2022Series A$12.4M
- Apr 2017Seed$626.6K
#9
Public · Torrance, California · founded 2017 · 9 employees$82.3Mraised▾
Forte Biosciences is a developer of therapeutic solutions for treating inflammatory skin diseases. The company has developed its lead topical product, FB-401 made of strains of a commensal gram-negative bacteria called as Roseomonas mucosa to treat inflammatory skin disease.
- Nov 2024Post IPO$37.9M
- Aug 2023Post IPO$25M
- Jun 2020Post IPO$19.4M
#10
Seed · Emeryville, California · founded 2022$2.9Mraised▾
Developer of enzyme ingredients for skin microbiome rebalancing. These ingredients are designed to selectively reduce harmful bacteria while preserving beneficial bacteria, addressing skin conditions like eczema and acne. The company utilizes a proprietary metagenomics platform to discover and develop these enzymes, harnessing natural biodiversity and synthetic biology. Rigorous laboratory research and clinical testing support the efficacy of these ingredients in restoring a healthy skin microbiome and improving overall skin health. The enzymes are formulated for use in skincare products.
- Jul 2025Grant (prize money)$1.5M
- Mar 2025Seed$1.4M
#11
Public · Carlsbad, California · founded 1990 · 75 employees$94Mraised▾
Developer of cell-based therapies for the treatment of cancer, eye disease, and spinal disorders. The company is using pluripotent and progenitor cells to develop terminally differentiated human cells for regenerative therapies. The cell therapy programs developed are OpRegen, which is a retinal pigment epithelium cells for dry age-related macular degeneration, OPC1 (oligodendrocyte progenitor cells for spinal cord injuries), and VAC2 that is an antigen-presenting dendritic cell for cancer immunotherapy. The company is developing a cell delivery device called Renevia for whole adipose tissue cell-assisted lipotransfer (CAL) in facial volume restoration procedures.
- Apr 2024Grant (prize money)—
- May 2023Grant (prize money)$50K
- Sep 2020Grant (prize money)$576.4K
- Aug 2020Post IPO$24.6M
#12
Funding Raised · Berkeley, California · founded 2021 · 4 employees$1.8Mraised▾
Developer of therapies to treat skin diseases through engineered skin probiotics. The company uses synthetic biology and metabolic engineering technology to develop a skin microbial platform to delivers therapies that address the causes of chronic skin diseases.
- Apr 2025Grant (prize money)$249.9K
- Sep 2022Grant (prize money)$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Dermatology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.